NorthWest Biotherapeutics Inc (NWBO)

[MI Dendream]

Also, KIPK these combo studies where everyone gets DCVAX but some are given add on are taking place in newly diagnosed GBM and are regulatory submitted.

The latest novel therapy pivotal trials approved to move forward by FDA are all in recurrent GBM. In terms of revenue potential, not only is that a much smaller population but you also have much shorter treatment duration potential. No one starts with the smaller subset if you can have the whole enchilada. So, they can’t have the whole enchilada because the new SOC was not available to them for trial.